Conventional and novel biomarkers of treatment outcome in patients with acromegaly: Discordant results after somatostatin analog treatment compared with surgery

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 717-726

  Rubeck, Kristine Z ^a   Madsen, Michael ^a   Andreasen, Caroline Marie ^a   Fisker, Sanne ^a   Frystyk, Jan ^a   Jørgensen, Jens Otto L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; FOLLITROPIN; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; INSULIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROTROPIN; BIOLOGICAL MARKER; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADENOMA; ADULT; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CORTICOTROPIN DEFICIENCY; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; EDEMA; EMBRYO; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HEALTH STATUS; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; MAXIMUM PLASMA CONCENTRATION; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL MOBILITY; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; SELF CARE; SKIN TINGLING; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TUMOR VOLUME; BLOOD; DRUG ANTAGONISM; FOLLOW UP; METABOLISM; MIDDLE AGED;

ACROMEGALY; ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77957848191     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0640     Document Type: Article

References (50)

1. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426. (doi:10.1210/jc.83.10. 3419)
2. Ch'ng LJ, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF & Bloom SR. Long term treatment of acromegaly with a long acting analogue of somatostatin. BMJ 1985 290 284-285. (doi:10.1136/bmj.290.6464.284-a)
3. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P & Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clinical Endocrinology 2008 69 299-305. (doi:10.1111/j.1365-2265.2008.03208.x)
4. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A & Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a meta analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 1743-1747. (doi:10.1210/jc.2006-2547) (Pubitemid 46997181)
5. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a meta analysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
6. Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008 159 89-95. (doi:10.1530/EJE-08-0267)
7. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Hormone and IGF Research 2003 13 171-184. (doi:10.1016/S1096-6374(03)00029-7)
8. Carmichael JD, Bonert VS, Mirocha JM & Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 523-527. (doi:10.1210/jc.2008-1371)
9. Parkinson C, Ryder WD & Trainer PJ. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. Journal of Clinical Endocrinology and Metabolism 2001 86 5240-5244. (doi:10.1210/jc.86.11.5240)
10. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE & Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism 2004 89 495-500. (doi:10.1210/jc.2003-031316)
11. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF & Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism 2002 87 3537-3542. (doi:10.1210/jc.87.8.3537)
12. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y & Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Journal of Clinical Investigation 2004 114 349-356. (doi:10.1172/JCI19933)
13. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K & Orskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973 2 1299-1301. (doi:10.1016/S0140-6736(73)92873-0)
14. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA & Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. Journal of Clinical Endocrinology and Metabolism 1993 77 267-272. (doi:10.1210/jc.77.1.267) (Pubitemid 23206814)
15. Frystyk J, Dinesen B & Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation 1995 5 169-176.
16. Chen JW, Ledet T, Ørskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen MB, Christiansen JS & Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. American Journal of Physiology. Endocrinology and Metabolism 2003 284 E1149-E1155. (doi:10.1152/ajpendo.00410.2002)
17. Jeyaratnaganthan N, Grønbaek H, Holland-Fischer P, Espelund U, Chen JW, Flyvbjerg A, Vilstrup H & Frystyk J. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clinical Endocrinology 2010 72 625-632. (doi:10.1111/j.1365-2265.2009.03707.x)
18. Frystyk J, Andreasen CM & Fisker S. Determination of free growth hormone. Journal of Clinical Endocrinology and Metabolism 2008 93 3008-3014. (doi:10.1210/jc.2008-0375)
19. Fisker S, Frystyk J, Skriver L, Vestbo E, Ho KK & Orskov H. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum. European Journal of Clinical Investigation 1996 26 779-785. (doi:10.1046/j.1365-2362.1996. 2010558.x)
20. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418. (doi:10.1210/jc.83.10.3411)
21. Freda PU, Post KD, Powell JS & Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3808-3816. (doi:10.1210/jc.83.11.3808)
22. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
23. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA & Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. Journal of Clinical Endocrinology and Metabolism 2004 89 2789-2796. (doi:10.1210/jc.2003-032041)
24. Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M & Ghigo E. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? Journal of Endocrinological Investigation 2004 27 1040-1047.
25. Machado EO, Taboada GF, Neto LV, vanHaute FR, Corrêa LL, Balarini GA, Shrank Y, Goulart M & Gadelha MR. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormone & IGF Research 2008 18 389-393. (doi:10.1016/j.ghir.2008.02.001)
26. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A & Arosio M. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism 2006 91 121-128. (doi:10.1210/jc.2005-1704)
27. Biermasz NR, Pereira AM, Frolich M, Romijn JA, Veldhuis JD & Roelfsema F. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American Journal of Physiology. Endocrinology and Metabolism 2004 286 E25-E30. (doi:10.1152/ajpendo.00230.2003) (Pubitemid 38036606)
28. Laursen T, Moller J, Fisker S, Jorgensen JO & Christiansen JS. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth Hormone & IGF Research 1999 9 451-457. (doi:10.1054/ghir. 1999.0131)
29. Pokrajac A, Frystyk J, Flyvbjerg A & Trainer PJ. Pituitary- independent effect of octreotide on IGF1 generation. European Journal of Endocrinology 2009 160 543-548. (doi:10.1530/EJE-08-0822)
30. Leung KC, Doyle N, Ballesteros M, Waters MJ & Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. Journal of Clinical Endocrinology and Metabolism 2000 85 4712-4720. (doi:10.1210/jc.85.12.4712) (Pubitemid 32157657)
31. Moller N, Bagger JP, Schmitz O, Jorgensen JO, Ovesen P, Moller J, Alberti KG & Orskov H. Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm. Journal of Clinical Endocrinology and Metabolism 1995 80 1789-1793. (doi:10.1210/jc.80.6.1789)
32. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL & Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. Journal of Clinical Endocrinology and Metabolism 1988 66 266-272. (doi:10.1210/jcem-66-2-266) (Pubitemid 18065166)
33. Ezzat S, Ren SG, Braunstein GD & Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. Journal of Clinical Endocrinology and Metabolism 1991 73 441-443. (doi:10.1210/jcem-73-2-441)
34. Ono M, Chia DJ, Merino-Martinez R, Flores-Morales A, Unterman TG & Rotwein P. Signal transducer and activator of transcription (Stat) 5b-mediated inhibition of insulin-like growth factor binding protein-1 gene transcription: a mechanism for repression of gene expression by growth hormone. Molecular Endocrinology 2007 21 1443-1457. (doi:10.1210/me.2006-0543)
35. Norrelund H, Fisker S, Vahl N, Borglum J, Richelsen B, Christiansen JS & Jørgensen JO. Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults. Growth Hormone & IGF Research 1999 9 52-60. (doi:10.1054/ghir.1998.0087)
36. Jorgensen JO, Moller N, Moller J, Weeke J & Blum WF. Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism 1994 43 579-583. (doi:10.1016/0026-0495(94)90199-6)
37. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P & Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism 2009 94 1500-1508. (doi:10.1210/jc.2008-2332)
38. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V & Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003 59 492-499. (doi:10.1046/j.1365-2265. 2003.01876.x)
39. Barkan AL, Beitins IZ & Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 1988 67 69-73. (doi:10.1210/jcem-67-1-69)
40. Alexopoulou O, Bex M, Abs R, T'sjoen G, Velkeniers B & Maiter D. Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 1324-1330. (doi:10.1210/jc.2007-2104)
41. Arafat AM, Möhlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schöfl C & Pfeiffer AF. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 2008 93 1254-1262. (doi:10.1210/jc.2007-2084)
42. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL & Thorner MO. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. Journal of Clinical Endocrinology and Metabolism 1987 64 51-58. (doi:10.1210/jcem-64-1-51)
43. Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism 1997 82 550-555. (doi:10.1210/jc.82.2.550) (Pubitemid 27068627)
44. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ & Ho KK. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. PNAS 2003 100 1016-1021. (doi:10.1073/pnas.0337600100) (Pubitemid 36183947)
45. Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS & Jørgensen JOL. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology 2005 152 719-726. (doi:10.1530/eje.1.01898) (Pubitemid 40744540)
46. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H & Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. American Journal of Physiology 1997 272 E1108-E1116. (Pubitemid 27293154)
47. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006 83 224-229. (doi:10.1159/000095532)
48. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA & Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. Journal of Clinical Endocrinology and Metabolism 2004 89 5369-5376. (doi:10.1210/jc.2004-0669) (Pubitemid 39518410)
49. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, Niskanen L, Reunanen A & Stenman UH. Quality of life in treated patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2006 91 3891-3896. (doi:10.1210/jc.2006-0676)
50. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM & van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 93 3853-3859. (doi:10.1210/jc.2008- 0669)